Leadership

Hepion leadership brings deep experience in the development and commercialization of targeted antiviral therapies for indications of important unmet need.

Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D.

Chief Executive Officer

Dr. Foster first began working on cyclophilin in 1988, and brings more than 30 years of pharmaceutical and biotech experience to Hepion. Prior to Hepion, he was CEO and Founder of Ciclofilin Pharmaceuticals Inc., which merged with Hepion in 2016. He founded Isotechnika Pharma Inc. (TSX:ISA) in 1993, and was its Chairman and CEO for approximately 21 years. Dr. Foster was founding CEO, and later CSO, of Aurinia (NASDAQ:AUPH) after it was acquired by Isotechnika. During his tenure at Isotechnika, Dr. Foster, together with a core team, discovered the immunosuppressive drug voclosporin. Learn More >>

John Cavan

Chief Financial Officer

John Cavan brings more than 20 years of financial management experience in both public and private companies. Prior to joining Hepion as CFO, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. receding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals. Learn More >>